941 related articles for article (PubMed ID: 29508169)
1. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
2. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome.
Birnbaum Y; Bajaj M; Qian J; Ye Y
BMJ Open Diabetes Res Care; 2016; 4(1):e000227. PubMed ID: 27547413
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
Birnbaum Y; Chen H; Tran D; Nylander S; Ye Y
Cardiovasc Drugs Ther; 2022 Oct; 36(5):829-840. PubMed ID: 34232433
[TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.
Birnbaum Y; Tran D; Bajaj M; Ye Y
Basic Res Cardiol; 2019 Aug; 114(5):35. PubMed ID: 31388770
[TBL] [Abstract][Full Text] [Related]
9. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
10. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
12. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
14. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk Among NLRP3 Inflammasome, ET
Muhammad RN; Ahmed LA; Abdul Salam RM; Ahmed KA; Attia AS
Neurotherapeutics; 2021 Oct; 18(4):2664-2681. PubMed ID: 34664178
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
Oe Y; Kim YC; Sidorenko VS; Zhang H; Kanoo S; Lopez N; Goodluck HA; Crespo-Masip M; Vallon V
Am J Physiol Renal Physiol; 2024 Feb; 326(2):F227-F240. PubMed ID: 38031729
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
18. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Schernthaner G; Mogensen CE; Schernthaner GH
Diab Vasc Dis Res; 2014 Sep; 11(5):306-23. PubMed ID: 25116004
[TBL] [Abstract][Full Text] [Related]
19. Reduced
Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
[TBL] [Abstract][Full Text] [Related]
20. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
